Drug intelligence / Profile preview

thiopental + pentobarbital

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of two barbiturate drugs (thiopental and pentobarbital) that produces synergistic central nervous system depression. It is used primarily in veterinary medicine and historically in human medicine. This combination is particularly effective for inducing anesthesia and controlling intracranial pressure. The typical formulation contains 750 mg of sodium thiopental and 250 mg of sodium pentobarbital per gram of powder, which is diluted with sterile water for injection. This combination is primarily used as an anesthetic for intravenous administration to dogs and cats during short to moderately long surgical procedures.

Other names: Thiopental and pentobarbital powder for injection

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on thiopental + pentobarbital.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiopental + pentobarbital.

Explore the full profile